Dovobet: Your Complete Guide to This Psoriasis Treatment

Dovobet is a prescription-only combination treatment for plaque psoriasis, containing two active ingredients that work through complementary mechanisms:

Calcipotriol (50 micrograms/g):

• A synthetic vitamin D3 analogue
• Slows the excessive growth of skin cells (keratinocytes) that causes the thickened, scaly plaques of psoriasis
• Has a mild anti-inflammatory effect

Betamethasone dipropionate (0.5 mg/g, equivalent to 0.064% betamethasone):

• A potent (group III) topical corticosteroid
• Provides rapid anti-inflammatory and immunosuppressive effects
• Reduces redness, itching and swelling

Available formulations:

• Dovobet Ointment: for psoriasis plaques on the trunk and limbs
• Dovobet Gel: designed specifically for scalp psoriasis, with a lighter consistency that is easier to apply to hair-bearing skin

Dovobet is also marketed under the name Daivobet in some European countries. The formulations are identical.

It is a well-established treatment recommended by NICE and the British Association of Dermatologists (BAD) for mild to moderate plaque psoriasis.

Correct application is essential for both effectiveness and safety.

Dovobet Ointment (body):

• Apply a thin layer to the affected areas once daily
• Use the fingertip unit (FTU) system to gauge the right amount: one FTU covers an area roughly the size of two adult palms
• Rub in gently until the ointment is absorbed
• Wash your hands thoroughly after application (unless you are treating the hands)
• The maximum weekly amount should not exceed 100 g
• The treated area should not exceed 30% of body surface area

Dovobet Gel (scalp):

• Apply to the affected areas of the scalp once daily
• Part the hair to expose the plaques and apply the gel directly
• Do not rub vigorously; allow the gel to absorb
• The maximum weekly amount should not exceed 60 g of gel on the scalp (or a combined maximum of 100 g if using both ointment and gel)

Duration of treatment:

• The BNF recommends an initial treatment period of up to 4 weeks for the body
• For the scalp, treatment can be continued for up to 8 weeks
• After a course of treatment, your prescriber may advise a break before repeating
• Continuous long-term use is not recommended due to the potent steroid component

Timing:

• Apply at the same time each day for consistency
• If you use a moisturiser (emollient), apply it at a different time (ideally at least 30 minutes before or after Dovobet) to avoid diluting the active ingredients

Most people tolerate Dovobet well. The following side effects are reported in clinical trials and post-marketing experience:

Common (more than 1 in 100 people):

• Skin irritation at the application site: itching, burning or stinging when first applied. This usually settles within a few days
• Pruritus (itching): may occur at or around the treated area

Uncommon (1 in 100 to 1 in 1,000):

• Folliculitis: inflammation of hair follicles, particularly on the scalp
• Skin thinning (atrophy): related to the steroid component, more likely with prolonged or excessive use
• Stretch marks (striae): rare with recommended treatment duration but possible with overuse
• Skin discolouration: temporary lightening or darkening of treated skin
• Exacerbation of psoriasis: paradoxically, some patients experience a flare. If this occurs, stop the treatment and contact your prescriber

Rare:

• Hypercalcaemia (raised blood calcium): related to calcipotriol absorption. The risk is minimised by staying within the recommended maximum weekly dose. Symptoms include excessive thirst, frequent urination and fatigue
• Allergic contact dermatitis: if you develop a new rash or the treated area worsens significantly

The steroid component makes it important to follow the recommended duration and dose limits.

Long-term continuous use of potent topical steroids can cause skin thinning, telangiectasia (visible blood vessels) and steroid dependence.

Dovobet is a prescription medicine and your prescriber will check that it is appropriate for you. The following precautions apply:

Do not use Dovobet on:

• The face (the facial skin is thin and particularly susceptible to steroid side effects)
• Skin folds (axillae, groin, under breasts) unless specifically directed by your dermatologist, as absorption is increased in these areas
• Broken or infected skin
• Areas of guttate, erythrodermic or pustular psoriasis (these forms require different treatment)

Contraindications:

• Known hypersensitivity to calcipotriol, betamethasone or any excipient
• Disorders of calcium metabolism (e.g. hypercalcaemia)
• Severe renal impairment (increased risk of calcipotriol-related hypercalcaemia)

Additional precautions:

• If you are using Dovobet on large areas, your prescriber may periodically check your blood calcium levels
• Avoid excessive sun exposure on treated areas (calcipotriol can increase photosensitivity)
• Do not use Dovobet under occlusive dressings unless directed, as this increases steroid absorption
• If you are pregnant or breastfeeding, discuss the risks and benefits with your prescriber. Potent topical steroids should be used with caution during pregnancy

Always inform your prescriber if your psoriasis changes in character (e.g. becomes pustular or more widespread) during treatment.

Understanding realistic expectations helps you get the most from Dovobet treatment.

When will I see results?

• Most patients notice improvement within 1 to 2 weeks
• The steroid component provides relatively rapid relief from redness and itching
• The calcipotriol component works more slowly, reducing plaque thickness over 2 to 4 weeks
• Maximum benefit is usually seen by the end of a 4-week course

How effective is Dovobet?

• Clinical trials show that the combination of calcipotriol and betamethasone is more effective than either ingredient alone
• In studies, approximately 60 to 70% of patients achieved "clear" or "almost clear" skin after 4 weeks of treatment
• Results vary depending on the severity and location of plaques

After treatment:

• Psoriasis is a chronic condition, and plaques often return after treatment is stopped
• Your prescriber may recommend a maintenance strategy using calcipotriol alone (without the steroid) between Dovobet courses
• Regular use of emollients (moisturisers) is recommended to keep the skin hydrated and reduce flare frequency

When Dovobet may not be enough:

• If your psoriasis is severe (affecting more than 30% of body surface area), systemic treatments may be more appropriate
• If Dovobet is not providing adequate control, your GP should consider referral to a dermatologist
• NICE recommends a step-up approach: emollients, then topical treatments (like Dovobet), then phototherapy, then systemic or biological therapies